Legend Biotech (ADR) (LEGN)
Commercializes CARVYKTI while developing next-generation CAR-T therapies.
Something off on this page? Send us feedback.
Commercializes CARVYKTI for multiple myeloma with Janssen and develops autologous, allogeneic, and in-vivo CAR-T programs. The business integrates cell-therapy discovery through commercialization and shares CARVYKTI economics with Janssen outside the PRC.
Commercializes CARVYKTI, a BCMA-directed autologous CAR-T therapy for multiple myeloma, with Janssen. The company integrates discovery, development, manufacturing, and commercialization; its operating footprint spans the United States, China, and Europe.
Its research portfolio covers investigational autologous, allogeneic, and in-vivo CAR-T approaches for blood cancers, solid tumors, and autoimmune diseases. LUCAR-G39D is an allogeneic candidate for B-cell non-Hodgkin lymphoma, while its in-vivo programs use the TaVec platform.
CARVYKTI is the commercial core, and its revenue, costs, and profits are shared equally with Janssen outside the PRC. Manufacturing capacity spans U.S., Chinese, and Belgian operations.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 4, 2026 | Morgan Stanley | Target | Target: $48 | Target: $65 |
| Aug 12, 2026 | Oppenheimer | Downgrade | Target: $75 | Target: $40 |
| Aug 12, 2026 | Barclays | Reiterate | Rating: —Target: $94 | Target: $78 |
| Jul 27, 2026 | Raymond James | Reiterate | Rating: —Target: — | Target: $58 |
| Jul 27, 2026 | RBC Capital | Reiterate | Rating: —Target: $63 | Target: $59 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $964.6M · Total debt $278.2M · Total assets $1.75B · Shareholders' equity $1.23B
- Revenue
- $387.5M
- Operating income
- $57.7M
- Net income
- $33.2M
No dividends on record.
| Institutions | 55.73% | 103.06M ADS | |
|---|---|---|---|
| 230 holders · as of Jun 30, 2026 | |||
| Insiders | 0.16% | 290.2K ADS | |
| 10 holders · as of Aug 18, 2026 | |||
| Strategic holders | 50.02% | 92.51M ADS | |
| 2 holders · as of Jan 29, 2024 | |||
| Adds to | 105.91% | ||
184.94M ADS (1 ADS = 2 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 105.91%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
GenScript Biotech CorporationStrategic | 47.18% | 87.25M | filed Mar 11, 2022 |
FMR LLCInstitution | 15.73% | 29.09M ADS | as of Jun 30, 2026 |
Hillhouse Investment Management, Ltd.Institution | 8.33% | 15.40M | filed Jul 12, 2021 |
Deerfield Management Company, L.P. (Series C)Institution | 4.40% | 8.14M ADS | as of Jun 30, 2026 |
Suvretta Capital Management, LLCInstitution | 3.82% | 7.07M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | Patrick John Casey | director | −6,000 | $14.80 |
| Jun 25, 2026 | Ying Huang | director, officer: Chief Executive Officer | −5,566 | $14.78 |
| Mar 25, 2026 | Ying Huang | director, officer: Chief Executive Officer | −9,936 | $8.77 |
- Bristol-Myers Squibb
BCMA CAR-T therapy for relapsed or refractory multiple myeloma
- Pfizer
BCMA bispecific antibody for relapsed or refractory multiple myeloma
- GSK (ADR)
Anti-BCMA regimen for relapsed or refractory multiple myeloma
- Regeneron
BCMA bispecific antibody for relapsed or refractory multiple myeloma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Legend Biotech (ADR) | $18.64 | +0.57% | $3.43B | — | 41.9 | 2.7 | +51.9% |
| Bristol-Myers Squibb | $62.61 | −0.02% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Pfizer | $27.84 | +0.34% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| GSK (ADR) | $50.78 | −0.60% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| Regeneron | $807.66 | +1.19% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Median | 17.9 | 9.9 | 2.5 | +5.5% |